Market Research Logo

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016’, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

The report provides comprehensive information on the Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13)
  • The report reviews Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) Overview
Therapeutics Development
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Stage of Development
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Therapy Area
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Indication
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Companies
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Universities/Institutes
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Companies Involved in Therapeutics Development
Advaxis, Inc.
American Gene Technologies International Inc.
Aprea AB
Cellceutix Corporation
Critical Outcome Technologies Inc.
Eleos Inc.
ORCA Therapeutics B.V.
OSE Pharma SA
PCI Biotech Holding ASA
Quark Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Shenzen SiBiono GeneTech Co., Ltd.
SK Biopharmaceuticals Co., Ltd.
Tara Immuno-Oncology Therapeutics LLC
Z53 Therapeutics, LLC
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Drug Profiles
Adxs-LmddA159 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APR-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APR-246 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATRN-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenersen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
contusugene ladenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COTI-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-12PGJ3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KM-3174 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MHY-449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MJ-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MX-225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Viruses to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSE-2101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
p28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPAL-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGT-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate p53 for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate p53 for Cancer and Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate p53 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZMC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Dormant Projects
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Discontinued Products
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Featured News & Press Releases
Apr 19, 2016: Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002
Feb 22, 2016: Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients
Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer
Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers
Feb 16, 2016: Cellceutix Completes Clinical Trial of Kevetrin for Advanced Solid Tumors
Feb 10, 2016: Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer
Feb 04, 2016: OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer
Jan 22, 2016: Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Advaxis, Inc., H1 2016
Pipeline by American Gene Technologies International Inc., H1 2016
Pipeline by Aprea AB, H1 2016
Pipeline by Cellceutix Corporation, H1 2016
Pipeline by Critical Outcome Technologies Inc., H1 2016
Pipeline by Eleos Inc., H1 2016
Pipeline by ORCA Therapeutics B.V., H1 2016
Pipeline by OSE Pharma SA, H1 2016
Pipeline by PCI Biotech Holding ASA, H1 2016
Pipeline by Quark Pharmaceuticals, Inc., H1 2016
Pipeline by Stemline Therapeutics, Inc., H1 2016
Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016
Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016
Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016
Pipeline by Z53 Therapeutics, LLC, H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Dormant Projects (Contd..2), H1 2016
Dormant Projects (Contd..3), H1 2016
Dormant Projects (Contd..4), H1 2016
Dormant Projects (Contd..5), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report